company background image
GNLX logo

Genelux NasdaqCM:GNLX Stock Report

Last Price

US$2.39

Market Cap

US$81.5m

7D

-0.4%

1Y

-84.1%

Updated

24 Dec, 2024

Data

Company Financials +

Genelux Corporation

NasdaqCM:GNLX Stock Report

Market Cap: US$81.5m

GNLX Stock Overview

A clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. More details

GNLX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Genelux Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genelux
Historical stock prices
Current Share PriceUS$2.39
52 Week HighUS$16.60
52 Week LowUS$1.60
Beta0
1 Month Change-6.27%
3 Month Change20.71%
1 Year Change-84.09%
3 Year Changen/a
5 Year Changen/a
Change since IPO-61.14%

Recent News & Updates

Genelux: H2 2025 PRROC Data Is A Major Inflection Point

Oct 31

We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

Aug 24
We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

Recent updates

Genelux: H2 2025 PRROC Data Is A Major Inflection Point

Oct 31

We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

Aug 24
We're Keeping An Eye On Genelux's (NASDAQ:GNLX) Cash Burn Rate

We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash Wisely

Jan 29
We're Hopeful That Genelux (NASDAQ:GNLX) Will Use Its Cash Wisely

We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn Rate

Sep 27
We're Not Very Worried About Genelux's (NASDAQ:GNLX) Cash Burn Rate

Shareholder Returns

GNLXUS BiotechsUS Market
7D-0.4%-3.3%-0.4%
1Y-84.1%-2.7%24.8%

Return vs Industry: GNLX underperformed the US Biotechs industry which returned -1.9% over the past year.

Return vs Market: GNLX underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is GNLX's price volatile compared to industry and market?
GNLX volatility
GNLX Average Weekly Movement13.3%
Biotechs Industry Average Movement10.7%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: GNLX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GNLX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200125Tom Zindrickwww.genelux.com

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer.

Genelux Corporation Fundamentals Summary

How do Genelux's earnings and revenue compare to its market cap?
GNLX fundamental statistics
Market capUS$81.51m
Earnings (TTM)-US$27.66m
Revenue (TTM)US$8.00k

Over9,999x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNLX income statement (TTM)
RevenueUS$8.00k
Cost of RevenueUS$0
Gross ProfitUS$8.00k
Other ExpensesUS$27.67m
Earnings-US$27.66m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.81
Gross Margin100.00%
Net Profit Margin-345,750.00%
Debt/Equity Ratio0%

How did GNLX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 13:28
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genelux Corporation is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bruce JacksonBenchmark Company
Brian Kemp DolliverBrookline Capital Markets
Michael SchmidtGuggenheim Securities, LLC